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Abstract
Background: Migraine and tension-type headache often occur comorbid with temporomandibular disorder; occlusal splint
therapy is the most common treatment for temporomandibular disorder. The aim of this study was to assess the effects of occlusal
splint therapy on headache symptoms in patients with migraine and/or tension-type headache comorbid with temporomandibular
disorder.
Methods: Sixty adult patients with migraine and/or tension-type headache and comorbid temporomandibular disorder were
randomly assigned to individualized occlusal splint therapy applied during day- and nighttime plus usual care (n=30) or usual care
alone (n=30). Primary outcome was the change in current pain intensity on a 100mm visual analogue scale from week 1 to week 12.
Secondary outcomes included changes in headache days and headache hours assessed by headache diaries over a 2-week period,
health-related quality of life (SF-36), and adverse events fromweek 1 to week 12 and (in the occlusal splint plus usual care group only)
to week 24.
Results: No group differences in changes in pain intensity from week 1 to week 12 were found. The number needed to treat was
3.8. Physical quality of life reduced stronger in the usual care group than in the occlusal splint plus usual care group. In the occlusal
splint plus usual care group, headache intensity significantly decreased and physical quality of life significantly increased from week 1
to week 12 and to week 24 (all P< .001). No adverse events were reported.
Conclusions:A day- and night-time occlusal splint therapy in addition to usual care was not superior to usual care alone in patients
with chronic headache and comorbid TMD. Four patients need to be treated to induce a minimal clinically relevant improvement in
one patient. The small sample size and lack of power limit these findings.
Abbreviations: CONSORT = Consolidated Standards of Reporting Trials, DIR = dynamic intraoral registration, ICD =
International Statistical Classification of Diseases and Related Health Problems, SF-36 = 36-health survey questionnaire, SPSS =
Statistical Package for Social Sciences, TMD = temporomandibular disorder, VAS = visual analogue scale.
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1. Introduction risk of chronic headache and can worsen existent primaryMigraine and tension-type headache often occur comorbid with
temporomandibular disorder (TMD).[1–4] TMD increases theEditor: Davor Plavec.
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headache.[5] A common central working mechanism of chronic
headache and TMD has been proposed, potentially involving
central sensitization of neurons due to peripheral nociceptive
input.[3,6] Patients comorbid with TMD and headache have been
characterized to suffer from a unique symptom complex that is no
longer fully representative of isolated headache.[7,8] It thus is
recommended to consider comorbid temporomandibular dis-
orders in the treatment of chronic headache.[3] Themost common
treatment of TMD is occlusal splint therapy. Occlusal splints alter
the position of the temporomandibular joint by influencing the
occlusal position, thereby changing activity patterns of the jaw
muscles during clenching.[9,10] Occlusal splint therapy can reduce
TMD-associated pain and muscle tenderness in the short-
term.[11] Functional magnetic resonance imaging data indicate,
that therapy with a splint can alter the activation of cerebral
regions that are linked to anticipation of pain.[12] Effectiveness
seems to be increased by day- and nighttime use of the splint
compared to overnight use only.[11]
For this randomized controlled trial, it was hypothesized that
there would be a stronger decrease in headache pain intensity in
patients with migraine and/or tension-type headache comorbid
with TMD during 12 weeks of occlusal splint therapy applied
Saha et al. Medicine (2019) 98:33 Medicineduring day- and nighttime plus usual care compared to usual care
alone. The aim of this randomized controlled trial was to test this
hypothesis. The splint was manufactured on the basis of a
reproducible, computerized analysis of the centric position of the
mandibular condyles.2. Methods
2.1. Design
This was an open-label single centered randomized controlled
trial conducted at the Department of Internal and Integrative
Medicine, Kliniken Essen-Mitte, Faculty of Medicine, University
of Duisburg-Essen, Essen, Germany. The study has been
approved by the University of Duisburg-Essen ethics committee
(approval number: 08-3596) and is reported in accordance with
the CONSORT (CONsolidated Standards of Reporting Trials)
2010 guideline.[13]2.2. Patients
Patients were recruited from the Department of Internal and
Integrative Medicine. Male and female patients were included if
they were at least 18 years old and were diagnosed with migraine
(ICD-10 G43.0/43.1) or chronic or episodic tension-type
headache (ICD-10 G44.2) at least 5 years ago and additionally
suffered from temporomandibular dysfunction. Patients had to
experience at least 5 monthly days of headache and had to be
physically and mentally capable to follow the study instructions.
Exclusion criteria included a suspected diagnosis of secondary
headache and depressive symptoms defined as values ≥8 on the
Hospital Anxiety and Depression Scale depression subscale.[14]
Potentially eligible patients received detailed written informa-
tion describing the study. They were assessed by a study
physician, and in case of correspondence to the inclusion/
exclusion criteria they were included in the trial, and written
informed consent was obtained.2.3. Randomization
Patients were randomly allocated 1:1 to occlusal splint therapy
plus usual care or usual care alone by drawing lots from a bag.
The lots were identical in appearance and prepared prior to
patient recruitment. Only when a patient was included in the
study and informed consent was obtained, a lot was drawn from
the bag and the patient was allocated to the respective group.2.4. Interventions
2.4.1. Occlusal splint therapy plus usual care. Patients in the
treatment group consulted a study dentist for functional
assessment using the “Dynamic Intraoral Registration” (DIR)
concept. Assessment included general and specific functional
medical history and manual examination (palpation) followed by
instrumental intraoral functional diagnostics. Using an electronic
support pin (in line with the Gysi/McGrane method), mandible
movements are encoded and recorded under defined chewing
power, followed by the positioning of the bite focusing on
physiologically ideal (centric) condyle positioning. This assess-
ment was performed by three dentists independently at the same
day in order to ensure reliability of the assessment. Based on this
instrumental functional diagnostics, an occlusal correction
therapy, giving the “ideal”, centric condyle position, is imitated2
using a DIR bite splint. Patients are advised to wear the splint
during day- and night-time and to only remove it for meals and
dental care for the following 24 weeks. Additional consultations
with the dentist were scheduled after 1, 6, 12, 13, and 18weeks to
check the function of the splint. Additionally at week 12, the
dentists’ assessment was repeated and the splint was refurbished.
Besides occlusal splint therapy, patients were allowed to continue
their usual activities and therapies, but not to initiate any new
therapeutic regimen for symptom management. Drugs and other
therapy use were not limited; their use was not assessed at study
entry or during the study period.
2.4.2. Usual care alone. Patients in this group received no
specific treatment but were advised to continue their usual
activities and therapies. They were asked not to initiate any new
therapeutic regimen for symptom management. Drugs and other
therapy use were not limited, and their use was not assessed at
study entry or during the study period. Patients were specifically
asked not to initiate an occlusal splint therapy during this period.
At week 12, they were offered the same therapy as the occlusal
splint therapy group. This was done to reduce dropout rates in
the control groups; it was hypothesized that a longer waiting
period would result in frustration in the control group patients.2.5. Outcome measures
Outcomes were assessed at 12 after randomization. In the
occlusal splint plus usual care group, they were additionally
assessed at week 24. Outcomes were not measured at week 24 in
the control group, because this group had already started occlusal
splint therapy at this time point, and could thus no longer serve as
an adequate control group. Change in current headache intensity
was defined as the primary outcome measure and measured using
a 0 to 100mm visual analogue scale (VAS) from the German Pain
Questionnaire with 0mm indicating ‘no pain at all’ and 100mm
indicating ‘worst pain imaginable’.[15] Predefined secondary
outcome measures included headache days and headache hours
over a 2-week period. Patients filled in a headache diary during
the 14 days before the respective assessment time point where
they indicated whether and for howmany hours they experienced
headache at a given day; and the frequency of headache days and
cumulative headache hours over the 14-days period was
calculated. Further, health-related quality of life was assessed
at each assessment time point using the short form 36-health
survey questionnaire (SF-36).[16] This 36-item instrument reliably
assesses physical andmental quality of life on 2 sum scores; scores
may range from 0 to 100 with higher ratings indicating a better
quality of life.2.6. Safety
All adverse events occurring during the study period were
recorded. Patients experiencing such adverse events were asked to
see the study physician to assess their import and initiate any
necessary response. Patients were asked to indicate any adverse
events during the study period regardless of their potential
relationship to the study intervention.2.7. Sample size calculation and statistical analysis
With a sample size of 30 patients per group, the study was
powered to detect a large group difference on the primary
Saha et al. Medicine (2019) 98:33 www.md-journal.comoutcome measure of d=0.8 with 80% power and a 2-sided a of
0.05 while accounting for a potential loss of power due to up to
10% of patients lost to follow-up.
All analyses were performed using the Statistical Package for
Social Sciences software (IBM SPSS Statistics for Windows,
release 22.0. Armonk, NY: IBM Group). Single missing values
were multiply imputed by Markov chain Monte Carlo
method.[17,18] To check for the potential impact of patients
stopping the study early, a per-protocol analysis was further
performed, including only patients that provided data at the
specific time point.
Baseline group differences in sociodemographic and clinical
data were analyzed using Student t tests for continuous data and
chi-square tests for categorical data. Between-group differences
in changes from week 1 to week 12 were analyzed using repeated
measures analyses of variance. The clinical relevance of the
findings was estimated by calculating the number of patients in
each group reaching a minimally clinically relevant improvement
of 10mm on the pain intensity VAS.[19] Based on these numbers,
the number needed to treat was calculated. Within group changes
in both groups were analyzed using Student t tests for dependent
samples. P values .05 were defined as statistical significant.3. Results
3.1. Patients
A total of 133 patients completed assessment by a study physician
and 73 of them were excluded because they did not meet
inclusion criteria (Fig. 1). Sixty patients were enrolled after
providing informed consent, and were randomized to occlusal
splint therapy plus usual care (n=30) or usual care alone (n=30).
A total of 4 patients in the occlusal splint therapy plus usual care
group (13.3%) were lost to follow up because they withdrew
consent before initiating the intervention (n=2) or stopped the
intervention early and contact was lost (n=2). Twelve patients in
the control group (40.0%) were lost to follow-up because they
withdrew consent (n=1) or contact was lost (n=11) (Fig. 1).Figure 1. Participa
3
There were no group differences in sociodemographic or clinical
characteristics (Table 1).
3.2. Outcomes
No group by time effects were found with regard to headache
intensity, headache days, headache hours, or physical quality of
life form week 1 to week 12 (Table 2). The number needed to
treat was 3.8. Mental quality of life slightly decreased in both
groups, this decrease was significantly larger in the usual care
alone group (P = .022). In the occlusal splint plus usual care
group, headache intensity significantly decreased and physical
quality of life significantly increased from week 1 to week 12 and
to week 24 (all P< .001). Headache days, headache hours and
mental quality of life did not change significantly. No within-
group changes occurred in the usual care alone group.
Findings of the per-protocol analysis, including only patients
that provided data at the specific time point, were comparable.3.3. Safety
No adverse events were reported.4. Discussion
This randomized controlled trial found no effects of occlusal
splint therapy plus usual care compared to usual care alone in
patients with migraine and/or tension-type headache and
comorbid TMD. While there was a significant group effect on
the secondary outcomemental quality of life, this variable slightly
decreased in both groups. The findings are however limited by the
small sample size and too low power of the study. The achieved
power in the study was 0.38 and thus a sample size of 172 would
have been needed to detect a group difference as in the present
study with a power of 0.80. Significant within-group effects
might be interpreted to warrant further studies in this type of
therapy using larger sample sizes with higher power. Especially
longer-term studies seem needed.nt flow diagram.
Table 1
Baseline sociodemographic and clinical characteristics. Values are expressed as means±standard deviations if not otherwise denoted.
Occlusal splint therapy plus usual care (n=26) Usual care alone (n=18) P value
Sociodemographic characteristics
Age, years 43.96±10,0 47.33±8,9 .258
Gender, female n (%) 24 (92.3%) 16 (89.0%) .698
Clinical characteristics
Main diagnosis n (%) .545
Migraine 24 (92.3%) 16 (88.9%)
Chronic tension-type headache 2 (7.7%) 2 (11.1%)
Additional diagnosis n (%) .545
Chronic tension-type headache 6 (20.0%) 0 (0.0%)
Episodic tension-type headache 2 (6.7%) 3 (10.0%)
Headache intensity (visual analog scale) 41.3±28.2 43.2±25.1 .819
Headache days 9.6±3.1 10.0±3.9 .742
Headache hours 118.6±80.2 110.7±80.1 .749
Health-related quality of life (SF-36)
Physical component summary 39.2±10.4 41.1±9.1 .417
Mental component summary 50.0±8.4 52.5±7.9 .410
Table 2
Effects of occlusal splint therapy plus usual care and usual care alone. Values are expressed as mean±standard deviation.
Occlusal splint therapy
plus usual care (n=26)
Usual care alone
(n=18) Group difference
(95% confidence interval) Week 12 P value
% missing
dataWeek 1 Week 12 Week 24 Week1 Week 12
Headache intensity 41.3±28.2 37.7±30.3 31.0±23.0 43.2±25.1 49.8±25.5 12.2 (29.1, 4.8) .283 4.5%
Headache days 9.6±3.1 7.6±5.1 6.8±5.2 10.0±3.9 7.1±5.4 0.5 (2.7, 3.7) .757 9.1%
Headache hours 118.6±80.2 92.7±88.4 79.0±91.0 110.7±80.1 78.0±91.0 14.7 (41.0, 70.5) .558 9.1%
SF-36
Physical component summary 39.2±10.4 44.3±10.5 44.3±13.1 41.1±9.1 40.5±8.8 3.8 (2.1, 9.7) .057 9.1%
Mental component summary 50.0±8.4 48.7±10.5 48.7±11.4 52.5±7.9 43.5±15.2 5.3 (2.5, 13.0) .022 9.1%
SF-36=36-health survey questionnaire.
Saha et al. Medicine (2019) 98:33 MedicineAccording to prior study results, occlusal splints can effectively
reduce pain and other symptoms in patients with TMD,[11]
however, their effects on symptoms of chronic headache have
only sparsely been investigated. Small pilot trials suggest limited
effectiveness of occlusal splint therapy in isolated migraine or
tension-type headache without comorbid TMD[20] while sus-
tained effects were found in patients with tension-type headache
and comorbid TMD.[21] In a prior 4-arm randomized trial on
patients comorbid with migraine and TMD, only a combined
treatment with propranolol and occlusal splint therapy induced
reduction in migraine symptoms while drug therapy or splint
therapy alone were ineffective.[6]
For TMD alone, a recent meta-analysis identified a total 33
randomized controlled trials of stabilization splints.[11] This
meta-analysis found significant short-term reductions but no
group differences in the longer term. Further short-term effects
were found on muscle tenderness and maximum mouth opening
but not for TMJ lateral and posterior tenderness reduction and
depression.[11] Interestingly, in individual studies, the majority
included no significant group differences, hinting at a potential
lack of power in each individual study. Likewise, although
significant within-group changes occurred in the occlusal splint
plus usual care group in the current study, the study most likely
was not powered to detect significant group differences. Thus,
larger studies with adequate power are needed to conclusively
judge the potential of this type of occlusal splint therapy in
patients with migraine and/or tension-type headache and
comorbid TMD.4
Occlusal splint therapy is thought to be effective in TMD
because this dysfunction’s symptoms are considered to
mainly arise from the strain of dealing with improper occlusal.
Occlusal splints are then thought to establish ideal maxilloman-
dibular relationships and thus relieve pain and restore the
function.[22]4.1. Limitations
There are a number of limitations in this study. The study sample
was rather small and the study thus underpowered. Moreover,
drop-out rates were high and not well balanced between groups.
This resulted in far more patients completing the study in the
treatment group than in the control group. Future studies should
focus on motivating patients especially in the control group to
remain in the study. However, the comparable findings in per-
protocol and intention-to-treat analyses hinted at a minor impact
of study drop-out. The use of placebo splints might increase
adherence to the study.[6] Treatments before and during the study
period were not assessed or compared between treatment groups.
Outcomes at week 24 were assessed in the occlusal splint therapy
group only in order to reduce waiting time in the control group. It
was hoped to reduce dropout rate in the control group by these
means; this however was not the case. Moreover, given that pain
intensity further improved in the occlusal splint therapy group
between weeks 12 and 24, it is likely that a potentially significant
and relevant long-term effect of the intervention was not detected
in this study.
Saha et al. Medicine (2019) 98:33 www.md-journal.com4.2. Implications for further research
In order to increase power for between-group differences, future
studies might investigate the effects of occlusal splint therapy in
larger samples of patients with TMD and chronic headache.
Strategies to maintain patients in the studies should be implemented
in future trials. Given that prefabricated splints have shown to
effectively reduce pain in patients with myofascial pain,[23] it should
be investigated whether this finding can also be applied to patients
with chronic headache. Given that the splints used in this trial were
fabricated individually after instrumental intraoral functional
diagnostics by specially trained dentists, a comparison of these
individual splints with prefabricated ones would have important
economic implications. Beyond that, comparisons with placebo
splints[6] as well as dose-finding studies investigating the most
effective length of use are needed. Most importantly, longer-term
group comparisons are needed to verify a potential effect of the
occlusal splint therapy after 6 months or longer treatment.
4.3. Implications for clinical practice
In conclusion, this study found only few effects of a 24-week day-
and night-time occlusal splint therapy might reduce headache
intensity in patients with chronic headache and comorbid TMD.
Although significant within-group changes were found, occlusal
splints cannot currently be recommended as a treatment option
for patients with migraine and/or tension-type headache who
additionally suffer from TMD. Based on the number needed to
treat, 4 patients need to be treated to achieve a minimally clinical
relevant difference in one patient. Given that these findings are
limited by lack of power and short follow-up periods, no clear
implications for clinical practice can be drawn.
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